- Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C2014 | First Faculty of Medicine
- Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis2015 | First Faculty of Medicine
- Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response2010 | Faculty of Medicine in Pilsen